# Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

> **NCT01175590** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 518 (actual)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** Besivance
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT01175590
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-12
- **Final completion:** 2012-02
- **Target enrollment:** 518 (ACTUAL)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01175590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01175590, "Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01175590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*